Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Stock Has Consensus Target Price of $6.40

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) has been given a consensus recommendation of “Moderate Buy” by the seven ratings firms that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, four have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $6.40.

A number of analysts have recently commented on the company. Cantor Fitzgerald initiated coverage on Milestone Pharmaceuticals in a research note on Thursday, August 20th. They set an “overweight” rating and a $3.00 price target on the stock. Zacks Research raised Milestone Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Monday, July 13th. HC Wainwright reiterated a “buy” rating on shares of Milestone Pharmaceuticals in a report on Thursday, September 3rd. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Milestone Pharmaceuticals in a research report on Tuesday, July 14th.

Milestone Pharmaceuticals Price Performance

Shares of NASDAQ:MIST opened at $0.79 on Monday. The company has a fifty day moving average of $1.09 and a 200-day moving average of $1.36. The company has a market capitalization of $98.16 million, a PE ratio of -1.14 and a beta of 0.98. The company has a debt-to-equity ratio of 3.25, a quick ratio of 7.92 and a current ratio of 8.13. Milestone Pharmaceuticals has a 52-week low of $0.75 and a 52-week high of $3.06.

Milestone Pharmaceuticals (NASDAQ:MIST) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.01). The company had revenue of $0.56 million during the quarter, compared to the consensus estimate of $0.82 million. On average, equities analysts predict that Milestone Pharmaceuticals will post -0.84 EPS for the current fiscal year.

Institutional Trading of Milestone Pharmaceuticals

Several institutional investors have recently modified their holdings of the business. Seven Fleet Capital Management LP acquired a new position in shares of Milestone Pharmaceuticals in the 1st quarter worth approximately $397,000. TRU Independence Asset Management 2 LLC acquired a new stake in shares of Milestone Pharmaceuticals during the second quarter worth $201,000. Renaissance Technologies LLC bought a new position in Milestone Pharmaceuticals during the first quarter worth $154,000. ADAR1 Capital Management LLC bought a new position in Milestone Pharmaceuticals during the second quarter worth $134,000. Finally, Guardian Wealth Advisors LLC NC lifted its holdings in Milestone Pharmaceuticals by 21.1% in the second quarter. Guardian Wealth Advisors LLC NC now owns 339,450 shares of the company’s stock valued at $455,000 after buying an additional 59,200 shares during the period. Institutional investors own 86.18% of the company’s stock.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals Inc is a biopharmaceutical company focused on developing therapies for cardiovascular conditions. The company’s lead product is etripamil, a short-acting, non-dihydropyridine calcium channel blocker formulated as a self-administered nasal spray.

Etripamil has been developed primarily for the rapid treatment of paroxysmal supraventricular tachycardia (PSVT), a form of abnormally fast heart rhythm that can begin and end suddenly. Milestone has also evaluated the therapy in other cardiovascular applications, including the potential treatment of angina and related conditions.

Founded in 2012, Milestone is headquartered in Montreal, Quebec, and has conducted clinical development activities in North America.